Reglan Tardive Dyskinesia Settlement: Statute of Limitations for Reglan in Massachusetts

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Targeted Risk Education

For decades, general health and science information has served as the foundation for public understanding of medication risks and patient safety. This broad educational framework has empowered individuals to recognize potential adverse effects associated with prescription drugs, fostering informed decision-making in clinical settings. Within this legacy, the focus has remained on universal health literacy, emphasizing the importance of reading labels, consulting physicians, and reporting unusual symptoms. However, as medical knowledge advances, certain medication-related risks demand more targeted attention—particularly those that emerge from prolonged or high-dose exposure in specific populations. The transition from general health awareness to occupational exposure concern becomes critical when considering drugs like Reglan (metoclopramide), commonly prescribed for gastrointestinal disorders. While the general public may be familiar with common side effects, the risk of tardive dyskinesia—a serious movement disorder—is often underappreciated outside specialized contexts. In Massachusetts, individuals who have taken Reglan for extended periods face unique legal and medical considerations, including strict statutes of limitations for filing claims. This shift in perspective moves beyond broad health education to address the specific vulnerabilities of those with sustained exposure, whether through prescribed treatment or occupational settings where the drug may be administered. The focus narrows from general risk awareness to the concrete implications of exposure duration, dosage, and legal recourse, highlighting the need for specialized guidance in navigating these complex intersections of medicine and law.

Understanding Reglan and Its Boxed Warning for Tardive Dyskinesia

Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information instructs clinicians to use Reglan for the shortest duration of treatment and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the label advises avoiding a total duration of treatment with metoclopramide products, including Reglan tablets, for longer than 12 weeks, and if longer-term use is unavoidable, to routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Clinical Presentation and Mechanism of Tardive Dyskinesia

Tardive dyskinesia is described as a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label also notes that metoclopramide may suppress or partially suppress the signs of TD and may delay the diagnosis of TD because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The boxed warning instructs that if signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label also warns against concomitant use of other drugs known to cause TD, other extrapyramidal symptoms, or neuroleptic malignant syndrome, and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to tardive dyskinesia involves the drug's dopamine receptor-blocking properties in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The label does not provide a detailed mechanistic explanation, but the clinical association is well-established through the boxed warning and warnings and precautions sections. The risk is dose-dependent and cumulative, with longer exposure increasing the likelihood of developing TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Legal Considerations and Statute of Limitations in Massachusetts

Regarding the adequacy of warnings, the FDA-approved labeling includes a boxed warning that clearly states the risk of TD, the need for short-term use, and the contraindication in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label also specifies that Reglan tablets are not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, despite these warnings, some patients may have been prescribed Reglan for longer than recommended durations, potentially leading to TD. The adequacy of warnings in individual cases may depend on whether prescribers and patients were adequately informed of the risks and whether the medication was used in accordance with the label. For affected patients in Massachusetts, settlement-related considerations involve the statute of limitations for filing a claim. In Massachusetts, the statute of limitations for personal injury claims, including those related to medication-induced TD, is generally three years from the date of injury or from when the injury was discovered or reasonably should have been discovered. The timeline between exposure to Reglan and documented harm is critical, as TD may develop months or years after starting the medication, and symptoms may persist or become irreversible even after discontinuation. The label states that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), so patients who used Reglan for extended periods may have a stronger basis for claims. Settlement amounts in TD cases can vary based on factors such as the severity of symptoms, duration of exposure, and evidence of inadequate warnings or off-label use. Patients considering legal action should consult with an attorney experienced in pharmaceutical litigation to assess the specific facts of their case, including the date of diagnosis, the duration of Reglan use, and whether the prescribing physician followed the label's recommendations. The boxed warning and other label sections provide clear documentation of the known risks, which may be used to support claims of inadequate warning if the prescriber failed to inform the patient or if the medication was used beyond the recommended duration.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to medication-induced tardive dyskinesia, is generally three years from the date of injury or from when the injury was discovered or reasonably should have been discovered. It is important to consult with an attorney to determine the specific deadlines applicable to your case.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) can cause tardive dyskinesia through its dopamine receptor-blocking properties in the basal ganglia, leading to supersensitivity of dopamine receptors and subsequent involuntary movements. The risk increases with longer duration of treatment and higher cumulative dosage, as noted in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.